- $268.12m
- $171.13m
- $114.70m
- 47
- 17
- 76
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.09 | ||
| Price to Tang. Book | 9.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.17% | ||
| Return on Equity | -122.54% | ||
| Operating Margin | -52.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 114.7 | 20.55 | 59.68 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Directors
- Faheem Hasnain CHM
- Bryan Giraudo CFO (45)
- Christian Waage EVP (54)
- Caryn Peterson EVP (62)
- Laura Carter CSO (54)
- Sandra Milligan DRC
- Joshua Bilenker IND (49)
- Kristina Burow IND (47)
- Russell Cox IND (57)
- Thomas Daniel IND (67)
- Renee Gala IND (49)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 26th, 2015
- Public Since
- February 8th, 2019
- No. of Shareholders
- 34
- No. of Employees
- 144
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 227,221,261
- Address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, 92121
- Web
- https://www.gossamerbio.com/
- Phone
- +1 8586841300
- Auditors
- Ernst & Young LLP
Upcoming Events for GOSS
Q2 2025 Gossamer Bio Inc Earnings Release
Similar to GOSS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Gossamer Bio share price?
As of Today at 20:55 UTC, shares in Gossamer Bio are trading at $1.18. This share price information is delayed by 15 minutes.
How has the Gossamer Bio share price performed this year?
Shares in Gossamer Bio last closed at $1.18 and the price had moved by +52.99% over the past 365 days. In terms of relative price strength the Gossamer Bio share price has outperformed the S&P500 Index by +37.95% over the past year.
What are the analyst and broker recommendations for Gossamer Bio?
The overall consensus recommendation for Gossamer Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Gossamer Bio dividend yield?
Gossamer Bio does not currently pay a dividend.
Does Gossamer Bio pay a dividend?
Gossamer Bio does not currently pay a dividend.
When does Gossamer Bio next pay dividends?
Gossamer Bio does not currently pay a dividend.
How do I buy Gossamer Bio shares?
To buy shares in Gossamer Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gossamer Bio?
As of the previous close price of $1.18, shares in Gossamer Bio had a market capitalisation of $268.12m.
Where are Gossamer Bio shares listed?
Here are the trading details for Gossamer Bio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GOSS
What kind of share is Gossamer Bio?
Based on an overall assessment of its quality, value and momentum Gossamer Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gossamer Bio share price forecast for 2025?
The analyst consensus target price for shares in Gossamer Bio is $6.21. That is 426.27% above the last closing price of $1.18.
Analysts covering Gossamer Bio currently have a consensus Earnings Per Share (EPS) forecast of -$0.69 for the next financial year.
Find out moreWhat is the trend in the Gossamer Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gossamer Bio. Over the past six months, its share price has outperformed the S&P500 Index by +35.68%.
As of the last closing price of $1.18, shares in Gossamer Bio were trading +21.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gossamer Bio PE Ratio?
The Gossamer Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gossamer Bio?
Gossamer Bio's management team is headed by:
- Faheem Hasnain - CHM
- Bryan Giraudo - CFO
- Christian Waage - EVP
- Caryn Peterson - EVP
- Laura Carter - CSO
- Sandra Milligan - DRC
- Joshua Bilenker - IND
- Kristina Burow - IND
- Russell Cox - IND
- Thomas Daniel - IND
- Renee Gala - IND